Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 30 January 2026, inter alia, have recommended the Third Interim dividend of Rs 3.5 per equity Share (i.e. 35%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Dr Lal Pathlabs declined 6.41% to Rs 90.50 crore in the quarter ended December 2025 as against Rs 96.70 crore during the previous quarter ended December 2024. Sales rose 10.57% to Rs 659.80 crore in the quarter ended December 2025 as against Rs 596.70 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales659.80596.70 11 OPM %27.1725.81 - PBDT196.50173.80 13 PBT154.40138.30 12 NP90.5096.70 -6 Powered by Capital Market - Live News

Dr Lal Pathlabs has allotted 4,000 equity shares under ESOP on 30 January 2026. Post this allotment, the paid up equity share capital has increased to Rs 1,67,55,50,200/- divided into 16,75,55,020 equity shares of Rs 10/- each.Powered by Capital Market - Live News

Dr Lal PathLabs announced the launch of Sovaaka, its new-age Diagnostic Experience Centre in Gurugram. Built on the philosophy of �Science Behind Wellness,� Sovaaka introduces a new standard in preventive and lifestyle healthcare. As an advanced wellness initiative from the house of Dr. Lal PathLabs, the centre brings together precision diagnostics, cutting-edge technology, and medical expertise to help individuals take proactive control of their health.Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks. Its doctor-designed programs � including Eterna (for women) and Vita (for men) � are customised to an individual`s age, gender, and lifestyle. It brings together advanced diagnostics such as high-sensitivity blood panels, genetic testing, AI-supported imaging, and seamlessly integrated digital health records. With end-to-end clinical report evaluation and tailored nutrition guidance, Sovaaka delivers a truly comprehensive, understanding of one`s health and wellness trajectory. The launch comes at a time when India is witnessing rapid growth in the preventive health and wellness segment, driven by increasing incidence of Non-Communicable Diseases, rising awareness, evolving lifestyles, and greater emphasis on early detection. With Sovaaka, Dr. Lal PathLabs takes a significant step forward in strengthening preventive care by offering comprehensive, evidence-backed solutions that empower individuals to understand their health better and act early.Powered by Capital Market - Live News

Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live News